Corneal permeability assay of topical eye drop solutions in rabbits by MRI

Abstract

This study examined the corneal permeability of topical eye drop solutions added with various corneal penetrating accelerators and gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA) by nuclear magnetic resonance imaging (MRI). Twenty-four New Zealand rabbits were randomly divided into 3 groups according to the random digits table: Gd-DTPA group, in which the rabbits received 23.45% Gd-DTPA; hyaluronic acid group, in which 23.45% Gd-DTPA plus 0.2% hyaluronic acid was administered; azone group, in which 23.45% Gd-DTPA with 0.2% azone was given. Fifty microliters of the eye drops was instilled into the conjunctive sac every 5 min, for a total of 6 applications in each group. Contrast medium signals in the cornea, anterior chamber, posterior chamber, and vitreous body were scanned successively by MRI. The morphology and cell density of the corneal endothelium were examined before and 24 h after the treatment. The results showed that the residence time of Gd-DTPA in the conjunctival sac in the hyaluronic acid and azone groups was longer than that in the Gd-DTPA group. The signals in the anterior chamber of the Gd-DTPA and hyaluronic acid groups were increased slightly, and those in the azone group strengthened sharply. The signal intensity continuously rose over 80 min before reaching plateau. The strengthening rate of signals in the anterior chamber was 19.63% in the Gd-DTPA group, 53.42% in the sodium hyaluronate group, and 226.94% in the azone group. No signal was detected in the posterior chamber or vitreous body in all the 3 groups. Corneal morphology and cell density did not show any significant changes after the treatment in all the 3 groups. It was concluded that azone can significantly improve the corneal permeability of drugs that are similar to Gd-DTPA in molecular weight and molecular size, and MRI is a noninvasive technique that can dynamically detect eye drop metabolism in real time.

References

[1] LudwigA.. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev, 2005, 57(11): 1595-1639

[2] WangK.D., ZhangJ.S., YanP.S.. Corneal permeability of topically applied pirenzepine solution. Zhonghua Yan Ke Za Zhi (Chinese), 2006, 42(6): 531-534

[3] SultanaY., AqilM., AliA., et al.. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol, 2006, 11(3): 313-319

[4] WangK.P., ZhangY., ShiC.Z., et al.. Preliminary Studies on the preparation of sodium taurocholate eyedrops and its pharmacodynamics. Acta Med Univ Sci Technol Huazhong (Chinese), 2002, 31(1): 21-23

[5] KearseE.C., GreenK.. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of Delta9-tetrahydrocannabinol. Curr Eye Res, 2000, 20(6): 496-501

[6] FurrerP., MayerJ.M., PlazonnetB., et al.. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS Pharm Sci, 2002, 4(1): E2

[7] YeniceI., MocanM.C., PalaskaE., et al.. Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res, 2008, 87(3): 162-167

[8] MishimaS.. Clinical pharmacokinetics of the eye. Invest Ophthalmol Vis Sci, 1981, 21(4): 504-541

[9] HosnyK.M.. Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. AAPS Pharm Sci Tech, 2009, 10(4): 1336-1342

[10] KompellaU.B., BandiN., AyalasomayajulaS.P.. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci, 2003, 44: 1192-1201

[11] FujitaE., TeramuraY., MitsugiK.. Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol Ther, 2008, 24(3): 333-343

[12] AkpekE.K., VittitowJ., VerhoevenR.S.. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther, 2009, 25(5): 433-439

[13] KimS.H., CsakyK.G., WangN.S., et al.. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res, 2007, 3: 1854-1866

[14] De FeoF., RoccatagliataL., BonzanoL.. Magnetic resonance imaging in patients implanted with Ex-PRESS stainless steel glaucoma drainage microdevice. Am J Ophthalmol, 2009, 147(5): 907-911

[15] MolokhiaS.A., JeongE.K., HiguchiW.I.. Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int J Pharm, 2007, 335(1–2): 46-53

[16] MolokhiaS.A., JeongE.K., HiguchiW.I.. Examination of barriers and barrier alteration in transscleral iontophoresis. J Pharm Sci, 2008, 97(2): 831-844

[17] LiS.K., JeongE.K., HastingsM.S.. Magnetic resonance imaging study of current and ion delivery into the eye during transscleral and transcorneal iontophoresis. Invest Ophthalmol Vis Sci, 2004, 45(4): 1224-1231

[18] LiS.K., MolokhiaS.A., JeongE.K.. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res, 2004, 21(12): 2175-2184

[19] BertR.J., CaruthersS.D., JaraH., et al.. Demonstration of an anterior diffusional pathway for solutes in the normal human eye with high spatial resolution contrast-enhanced dynamic MR imaging. Invest Ophthalmol Vis Sci, 2006, 47(12): 5153-5162

[20] XuY., ChenZ., SongJ., et al.. Azone-induced changes on corneal endothelium in rabbits. Zhonghua Yan Ke Za Zhi (Chinese), 1998, 34(1): 25-27

[21] Tang-LiuD.D., RichmanJ.B., WeinkamR.J.. Effects of four penetration enhancers on corneal permeability of drugs in vitro. J Pharm Sci, 1994, 83(1): 85-90

[22] IsmailI.M., ChenC.C., RichmanJ.B.. Comparison of azone and hexamethylene lauramide in toxicologic effects and penetration enhancement of cimetidine in rabbit eyes. Pharm Res, 1992, 9(6): 817-821

[23] ChanK.C., FuQ.L., GuoH.. GD-DTPA enhanced MRI of ocular transport in a rat model of chronic glaucoma. Exp Eye Res, 2008, 87(4): 334-341

[24] BertR.J., CaruthersS.D., JaraH.. Demonstration of an anterior diffusional pathway for solutes in the normal human eye with high spatial resolution contrast-enhanced dynamic MR imaging. Invest Ophthalmol Vis Sci, 2006, 47(12): 5153-5162